Maxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5

Benzinga Newsdesk www.benzinga.com Neutral 73.5%

Neg 0% Neu 73.5% Pos 0%

Maxim Group analyst Jason McCarthy initiates coverage on Mira Pharmaceuticals (NASDAQ:MIRA) with a Buy rating and announces Price Target of $3.5.